Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights a decrease in revenue and an increase in net loss, which are negative indicators. There were no positive updates on shareholder returns or operational advancements. The Q&A section didn't provide additional insights to offset these negatives. The financial outlook, while supporting operations into 2027, doesn't mitigate the immediate concerns of declining revenues and increased losses. Without a market cap, a conservative negative rating is given based on these financial metrics and lack of positive catalysts.
Key Financial Performance
Revenue Curis reported revenue of $2.3 million for Q1 2026, which represents a 15% decrease year-over-year. The decline was attributed to lower royalty revenues from Erivedge due to reduced sales.
Net Loss The net loss for Q1 2026 was $8.7 million, compared to $7.5 million in Q1 2025, reflecting a 16% increase year-over-year. This was primarily due to higher research and development expenses.
Research and Development Expenses R&D expenses increased to $6.2 million in Q1 2026 from $5.1 million in Q1 2025, marking a 21.6% increase year-over-year. The rise was driven by increased spending on clinical trials and drug development activities.
General and Administrative Expenses General and administrative expenses were $3.1 million for Q1 2026, up from $2.8 million in Q1 2025, showing a 10.7% increase year-over-year. The increase was due to higher personnel-related costs.
Cash Position As of March 31, 2026, Curis had $22.5 million in cash, cash equivalents, and investments, compared to $25.8 million as of December 31, 2025. The decrease was due to operational expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements and uncertainties: The company acknowledges that forward-looking statements are subject to certain risks and uncertainties, which could lead to material differences in actual results.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Steady Progress: We continue to make steady progress in our strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
Ben Hail
CFO Principal
Co LLC
Conference Instructions
Curis Update
Danya Ben
Director Chief
Division Yale
Division afternoon
Dr Chief
EDT Danya
Financial Accounting
HC Wainwright
Hail JonesTrading
Institutional Services
Instructions Tuesday
JonesTrading Institutional
LLC Research
Laidlaw PM
Nik HC
Officer CFO
Officer Curis
Officer President
Officer Sara
PM EDT
Principal Financial
Research Division
Sara Nik
Services LLC
Tuesday conference
conference Chief
gentleman Curis
CRIS Transcript
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary highlights a decrease in revenue and an increase in net loss, which are negative indicators. There were no positive updates on shareholder returns or operational advancements. The Q&A section didn't provide additional insights to offset these negatives. The financial outlook, while supporting operations into 2027, doesn't mitigate the immediate concerns of declining revenues and increased losses. Without a market cap, a conservative negative rating is given based on these financial metrics and lack of positive catalysts.
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call reveals a mixed picture. While there is a positive net income due to a one-time gain, the company faces ongoing financial losses and operational risks. The lack of revenue for 2026 and dependence on future financing are concerns. However, the optimistic guidance for clinical trials and reduced expenses are positive. The Q&A session highlights challenges in trial enrollment and management's reluctance to provide specifics, adding uncertainty. Given these factors, the stock price is expected to remain stable in the short term, leading to a neutral sentiment rating.
Curis, Inc. (CRIS) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call highlights several risks, including regulatory challenges, financial constraints, and competition. The company reported a net loss, though reduced compared to the previous year, and has limited cash reserves. The Q&A section reveals a lack of detailed guidance and an emphasis on securing additional capital, indicating financial strain. Despite some positive clinical updates, the overall sentiment leans negative due to financial and strategic uncertainties.
Curis, Inc. (CRIS) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Neutral9-11
CRIS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
